Prime Medicine

Gene editing: overhyped or unstoppable tide?

A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.

January 05, 2023

Flotations fail to bounce back

2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.

October 04, 2022

The biopharma flotation remains a rare beast

Few developers are feeling bold enough to brave the markets, though the bigger deals are finding some support.